Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab
Our results suggest that PFS and OS are negatively affected by elevated CXCL9, CXCL10, and CCL23 levels after CCRT followed by durvalumab treatment. These soluble mediators may be useful tools for the clinical management of locally advanced NSCLC treated with PD-L1 therapy after CCRT.
Authors
- Tetsuro Sasada (ORCID: https://orcid.org/0000-0002-2313-8833)
- Kenta Murotani (ORCID: https://orcid.org/0000-0003-0623-9365)
- Koichi Azuma (ORCID: https://orcid.org/0000-0001-5040-5856)
- Tomoaki Hoshino (ORCID: https://orcid.org/0000-0002-0459-4913)
- Takaaki Tokito (ORCID: https://orcid.org/0000-0002-8429-2287)
- Goushi Matama
- Norikazu Matsuo
- Daiki Murata (ORCID: https://orcid.org/0000-0002-4295-5046)
Institutions
- Kurume University (JP)
- Kanagawa Prefectural Hospital Organization (JP)
- Kanagawa Cancer Center
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tlcr-2025-563
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00